<var id="bxdpz"></var>
<var id="bxdpz"><video id="bxdpz"><thead id="bxdpz"></thead></video></var>
<cite id="bxdpz"></cite><var id="bxdpz"></var>
<var id="bxdpz"></var>
<ins id="bxdpz"><noframes id="bxdpz"><cite id="bxdpz"></cite>
<cite id="bxdpz"></cite>
<var id="bxdpz"><dl id="bxdpz"></dl></var>
<var id="bxdpz"><dl id="bxdpz"></dl></var>
<var id="bxdpz"><video id="bxdpz"><menuitem id="bxdpz"></menuitem></video></var>
巴彥淖爾癲癇醫院

2013年的國際抗癲癇聯合會抗癲癇藥使用指南

2022-04-26 00:23:45 來源:巴彥淖爾癲癇醫院 咨詢醫生

he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.

The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.

This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.

New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.

There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.

These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.

查看信源郵箱

TAG:
推薦閱讀
久久久久久精品免费免费直播,国产精品978在线播放,精品一卡二卡三卡分类